Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 53Lung Neoplasms 24Breast Neoplasms 22Head and Neck Neoplasms 14Adenocarcinoma of Lung 11Neoplasms 7Esophageal Neoplasms 7Brain Neoplasms 7Prostatic Neoplasms 6Adenocarcinoma, Bronchiolo-Alveolar 6Neoplasm Metastasis 5Glioblastoma 5Adenocarcinoma Of Esophagus 5Squamous Cell Carcinoma of Head and Neck 4Rectal Neoplasms 4Ovarian Neoplasms 4Gliosarcoma 4Colorectal Neoplasms 4Colonic Neoplasms 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Skin Neoplasms 2Neoplasms, Squamous Cell 2Mesothelioma, Malignant 2Lymphoid Interstitial Pneumonia 2Laryngeal Diseases 2

Interventions

Pemetrexed 10Cisplatin 9Gemcitabine 8Nivolumab 5Ipilimumab 4Carboplatin 4niraparib 3durvalumab 3Vinorelbine 3Bevacizumab 3tremelimumab 2pembrolizumab 2olaparib 2anetumab ravtansine 2Radiotherapy, Intensity-Modulated 2Oxaliplatin 2Imatinib Mesylate 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorodeoxyglucose F18 2Cytoreduction Surgical Procedures 2vandetanib 1tislelizumab 1tazemetostat 1spartalizumab 1sargramostim 1ribociclib 1fludarabine phosphate 1fludarabine 1dostarlimab 1defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma × Gefitinib × Clear all
NCT00787410 2012-06-06

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

AstraZeneca

Phase 2 Completed
23 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡